FULC
Fulcrum Therapeutics, Inc.Price
Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).
- Jan 2 ▼ 1 insider sell $163.1K at $10.87
- Feb 2 ▼ 1 insider sell $160.9K at $10.72
- Jun 1 Activist stake: Fulcrum Therapeutics Announces Discontinuation of Pociredi…
- Jun 2 ▼ 5 downgrades
- Jun 26 ▼ 1 insider sell $65.6K at $3.65
- Jul 13 to Jul 17 ▲ 5 days of insider buys: $1.5M by 1 insider, avg $3.56
- Aug 17 ▲ Fulcrum Therapeutics (FULC) and Slate Medicines announced a definiti…
- Aug 17 ▲ Fulcrum Therapeutics (FULC) entered into a definitive merger agreeme…
- Aug 17 ▲ Fulcrum Therapeutics is being acquired by Slate Medicines in an all-…
- Aug 17 ▼ Fulcrum Therapeutics (FULC) filed a Rule 425 transcript of a joint c…
- Sep 1 ▼ Fulcrum Therapeutics (FULC) filed an S-4 registration statement for…
- Oct 20 ▼ Fulcrum Therapeutics (FULC) filed Amendment No. 2 to its S-4 registr…
Signal stack
Where each data set points today.
- InsidersBULLISH
1 insider bought $1.5M at an average $3.56. 2 insiders sold $389.6K.
- InstitutionsMIXED
Q3 2026: 20 added (0 new), 16 trimmed or exited.
- Short sellersSTEADY
Short interest −4.7% to 6.44M shares. 4.8 days to cover, ≈8.4% of shares.
- TrendRANGE
1% below its 50-day average.
Who's buying
13F· Q3 2026| Fund | Move | Value |
|---|---|---|
| BlackRock, Inc. | ADD | $43.0M |
| RENAISSANCE TECHNOLOGIES LLC | ADD | $8.2M |
| MARSHALL WACE, LLP | ADD | $7.0M |
| STATE STREET CORP | TRIM | $4.7M |
| FMR LLC | DOUBLED | $2.4M |
| JANE STREET GROUP, LLC | NEAR_EXIT | $1.9M |
| Jump Financial, LLC | TRIM | $1.6M |
| MORGAN STANLEY | ADD | $1.2M |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
Last action Jun 2026Price is inside the target range. Median implies +8%.Targets as of Nov 17, 2026.
| Date | Firm | Rating |
|---|---|---|
| Jun 3, 2026 | JP Morgan DOWNGRADE | Underweight |
| Jun 2, 2026 | Stifel DOWNGRADE | Hold |
| Jun 2, 2026 | Piper Sandler DOWNGRADE | Underweight |
| Jun 2, 2026 | Truist Securities DOWNGRADE | Hold |
| Jun 2, 2026 | Leerink Partners DOWNGRADE | Market Perform |
| Jun 2, 2026 | HC Wainwright & Co. DOWNGRADE | Neutral |
Insider ledger
Form 4| Insider | Type | Value |
|---|---|---|
TANG KEVIN 10%+ Owner Jul 17, 2026 | BUY | $179.3K |
TANG KEVIN 10%+ Owner Jul 16, 2026 | BUY | $415.3K |
TANG KEVIN 10%+ Owner Jul 15, 2026 | BUY | $382.3K |
TANG KEVIN 10%+ Owner Jul 14, 2026 | BUY | $271.9K |
TANG KEVIN 10%+ Owner Jul 14, 2026 | BUY | $191.0K |
TANG KEVIN 10%+ Owner Jul 13, 2026 | BUY | $45.9K |
King Rachel K. Director Jun 30, 2026 | AWARD | 32,000 sh |
Gould Robert J Director Jun 30, 2026 | AWARD | 32,000 sh |
Earnings setup
EstimatesRevision history: 🔒 Fresh data, subscribers only
| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | 🔒 Fresh data, subscribers only | |||
| Next Q | -$0.36 | -$0.36–-$0.36 | -30.1% | $0.00 |
| Current FY | 🔒 Fresh data, subscribers only | |||
| Next FY | 🔒 Fresh data, subscribers only | |||
Washington
Short side
FINRA· Oct 30, 2026SecBot reports
21 filings · 2 press releases · 3 bullish · 3 bearish · 2 mixed · 13 neutral- NEUTRAL SC 13GNov 16, 2026
ADAR1 Capital Management, LLC and its manager Daniel Schneeberger filed a Schedule 13G disclosing a passive 8.7% stake (6,648,027 shares) in Fulcrum Therapeutics as of September 30, 2026. This is an initial filing for this filer, indicating a new passive position in the micro-cap biotech.
🔒 Fresh report (last 24h), subscribers only
- NEUTRAL SC 13G/ANov 16, 2026
EcoR1 Capital, LLC and related entities filed an amended Schedule 13G disclosing a passive 8.9% stake (6,803,785 shares) in Fulcrum Therapeutics as of September 30, 2026. This is a routine quarterly update for a passive investment adviser and does not signal activist intent.
🔒 Fresh report (last 24h), subscribers only
- NEUTRAL SC 13G/ANov 13, 2026
Nantahala Capital Management disclosed a passive 8.62% stake in Fulcrum Therapeutics as of…
Monitor for any future conversion to a Schedule 13D, which would signal activist intent. For now, the passive filing suggests no immediate change in strategy.
- NEUTRAL SC 13G/ANov 13, 2026
Montanova Capital LLC and affiliated entities filed an amended Schedule 13G disclosing they no…
Monitor for any new 13D or 13G filings from other holders that could indicate changing ownership dynamics. The exit by a passive manager is routine and does not alter the fundamental outlook.
All FULC filing & press-release reports (23)
- SC 13G reportNov 16, 2026
- SC 13G/A reportNov 16, 2026
- SC 13G/A reportNov 13, 2026
- SC 13G/A reportNov 13, 2026
- 425 reportNov 12, 2026
- 8-K reportNov 12, 2026
- EFFECT reportNov 5, 2026
- S-4/A reportNov 3, 2026
- SC 13G/A reportOct 28, 2026
- SC 13G/A reportOct 27, 2026
- S-4/A reportOct 20, 2026
- S-4/A reportOct 8, 2026
- S-4 reportSep 1, 2026
- 425 reportAug 17, 2026
- 425 reportAug 17, 2026
- 8-K reportAug 17, 2026
- PRESS-RELEASE reportAug 17, 2026
- 8-K reportAug 10, 2026
- 3 reportJul 15, 2026
- INST-CLUSTER reportJun 11, 2026
- 8-K reportApr 27, 2026
- PRESS-RELEASE reportApr 27, 2026
- PRESS-RELEASE reportMar 19, 2026